ArticleCancer reports (Hoboken, N.J.)2026
Dual Role of LBH589 in Triple-Negative Breast Cancer: Inhibition of Tumor Growth and Enhancement of Antitumor Immunity.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic reprogramming and immune evasion interaction in the tumor microenvironment promote tumor progression.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEpigenetic dysregulation, particularly aberrant histone deacetylase (HDAC) activity, plays a critical role in the progression of breast cancer. Although HDAC inhibitors (HDACi) have demonstrated antitumor potential in preclinical studies, none have been approved for breast cancer due to inconsistent efficacy across different subtypes. Panobinostat (LBH589), a pan-HDACi with favorable pharmacological properties, has shown clinical efficacy in multiple myeloma and other malignancies, but its role in breast cancer remains insufficiently studied. METHODS AND
resultsIn this study, the effects of LBH589 on triple-negative breast cancer (TNBC) were systematically investigated. Results revealed that LBH589 downregulated c-myc, disrupted the epithelial-mesenchymal transition (EMT) program, inhibited proliferation, migration, and invasion, and induced apoptosis. Moreover, LBH589 enhanced tumor immunogenicity by upregulating MHC I/II antigen presentation pathways, thereby promoting dendritic cell maturation. In vivo, LBH589 markedly induced tumor apoptosis and inhibited growth, accompanied by increased proportions of CD8
conclusionOur study demonstrates that LBH589 not only directly induces apoptosis, inhibits proliferation, migration, and invasion, but also enhances the anti-tumor immune response through improving tumor immunogenicity. These findings not only broaden the mechanistic understanding of HDACi in TNBC, but also provide a theoretical basis for combining epigenetic therapy with immunotherapy, supporting LBH589 as a potential immunotherapy sensitizer for triple-negative breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.